Trial Profile
Efficacy and safety of rivastigmine in patients with mild cognitive impairment
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2008
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- Sponsors Novartis
- 05 Sep 2006 New trial record.